Table 3 Demographic data of patients taking predominant sodium channel blocking antiseizure medications
|  | All (n = 82) | Response (n = 58) | Not seizure-free (n = 24) | p |
|---|---|---|---|---|
Onset age (year) | 17.5 (12.8–26.0) | 15.0 (8.0–19.0) | 19.0 (15.0–28.0) | 0.020 |
Male | 34 (41.5) | 24 (41.4) | 10 (41.7) | reference |
Female | 48 (58.5) | 34 (58.6) | 14 (58.3) | 0.981 |
Seizure type | ||||
 Focal | 51 (62.2) | 34 (58.6) | 17 (70.8) | 0.382 |
 Generalized | 17 (20.7) | 12 (20.7) | 5 (20.8) |  |
 Unspecified | 14 (17.1) | 12 (20.7) | 2 (8.3) |  |
Etiology | ||||
 Structural | 13 (15.9) | 8 (13.8) | 5 (20.8) | 0.072 |
 CNS infection | 4 (4.9) | 3 (5.2) | 1 (4.2) |  |
 Genetic | 1 (1.2) | 0 (0.0) | 1 (4.2) |  |
 Autoimmune | 2 (2.4) | 0 (0.0) | 2 (8.3) |  |
 Unknown | 62 (75.6) | 47 (81.0) | 15 (62.5) |  |
Number of ASMs | ||||
 1 | 46 (56.1) | 40 (69.0) | 6 (25.0) |  |
 2 | 23 (28.0) | 13 (22.4) | 10 (41.7) |  |
 3 | 12 (14.6) | 5 (8.6) | 7 (29.2) |  |
 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 5 | 1 (1.2) | 0 (0.0) | 1 (4.2) |  |
Concurrent ASMs | ||||
 Carbamazepine | 29 | 21 | 8 |  |
 Clobazam | 3 | 2 | 1 |  |
 Gabapentin | 1 | 0 | 1 |  |
 Lacosamide | 2 | 0 | 2 |  |
 Lamotrigine | 34 | 24 | 10 |  |
 Levetiracetam | 24 | 10 | 14 |  |
 Oxcarbazepine | 10 | 6 | 4 |  |
 Perampanel | 1 | 0 | 1 |  |
 Phenobarbital | 1 | 0 | 1 |  |
 Phenytoin | 27 | 18 | 9 |  |
 Vigabatrin | 1 | 0 | 1 |  |